Investment analysts at StockNews.com initiated coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research report issued on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
The company has a market capitalization of $6,000.00, a price-to-earnings ratio of 0.00 and a beta of 1.61. The company has a current ratio of 1.35, a quick ratio of 1.35 and a debt-to-equity ratio of 0.24. Genocea Biosciences has a twelve month low of $0.00 and a twelve month high of $0.00.
Genocea Biosciences Company Profile
See Also
- Five stocks we like better than Genocea Biosciences
- Overbought Stocks Explained: Should You Trade Them?
- Build-Your-Bowl Battle: CAVA, Chipotle, and Sweetgreen Face Off
- The Significance of Brokerage Rankings in Stock Selection
- Insiders Are Loading Up: 3 Key Stock Picks for Investors
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- How Cigna Remains at the Top of the Health Insurance Food Chain
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.